Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 4;222(8):e20250272.
doi: 10.1084/jem.20250272. Epub 2025 Jun 5.

YTHDFs as radiotherapy checkpoints in tumor immunity

Chuangyu Wen  1   2 , Emile Z Naccasha  1   2 , Chuan He  3   4 , Hua Laura Liang  1   2 , Ralph R Weichselbaum  1   2
Affiliations
Review

YTHDFs as radiotherapy checkpoints in tumor immunity

Chuangyu Wen et al. J Exp Med. .

Abstract

Radiotherapy (RT), a cornerstone of cancer treatment, exerts its therapeutic effects primarily by inducing DNA damage in tumor cells and modulating the tumor immune microenvironment (TIME). Despite its efficacy, RT is often counteracted by tumor-intrinsic mechanisms, such as DNA damage repair, as well as immune-suppressive responses. YTHDF proteins, key N6-methyladenosine (m6A) readers, have emerged as pivotal regulators of tumor progression, DNA repair, and immune cell function, making them promising targets for enhancing RT efficacy. In this review, we explore the dual roles of YTHDF proteins in modulating both tumor-intrinsic and immune-mediated responses to RT. We summarize their influence on DNA damage repair pathways in tumor cells and their impact on the TIME, which collectively shape the antitumor efficacy of RT. Furthermore, we discuss recent advances in the development of YTHDF-targeting inhibitors and their potential to synergize with RT and immunotherapy, offering new avenues to improve cancer treatment outcomes.

PubMed Disclaimer

Conflict of interest statement

Disclosures: C. He reported serving as a scientific co-founder and as a member of the scientific advisory board for Aferna Green, Inc., AllyRNA Inc, and Ellis Bio, Inc. Additionally, C. He holds equity in Aferna Green, Inc., Ellis Bio, Inc., AllyRNA, Inc., and Accent Therapeutics, Inc. R.R. Weichselbaum has stock and other ownership interests with Boost Therapeutics, Immvira LLC, Reflexion Pharmaceuticals, Coordination Pharmaceuticals Inc., Magi Therapeutics, Oncosenescence, Aqualung Therapeutics Corporation, Cyntegron, Fuse Oncology, and PersonaDX. He has served in a consulting or advisory role for Aettis Inc., AstraZeneca, Coordination Pharmaceuticals, Genus, Merck Serono S.A., Nano Proteagen, NKGen Biotech, Shuttle Pharmaceuticals, Highlight Therapeutics, S.L., Aqualung Therapeutics Corporation. In addition, R.R. Weichselbaum has received industry research grants from Varian and Regeneron, and holds patents on metastasis signatures and cGAS-STING IR. No other disclosures were reported.

Similar articles

See all similar articles

References

    1. Antonia, S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K.H., de Wit M., et al. 2017. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377:1919–1929. 10.1056/NEJMoa1709937 - DOI - PubMed
    1. Azzam, E.I., Jay-Gerin J.-P., and Pain D.. 2012. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett. 327:48–60. 10.1016/j.canlet.2011.12.012 - DOI - PMC - PubMed
    1. Bai, X., Wong C.C., Pan Y., Chen H., Liu W., Zhai J., Kang W., Shi Y., Yamamoto M., Tsukamoto T., et al. 2022. Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells. J. Immunother. Cancer. 10:e003663. 10.1136/jitc-2021-003663 - DOI - PMC - PubMed
    1. Bao, Y., Zhai J., Chen H., Wong C.C., Liang C., Ding Y., Huang D., Gou H., Chen D., Pan Y., et al. 2023. Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut. 72:1497–1509. 10.1136/gutjnl-2022-328845 - DOI - PMC - PubMed
    1. Brandmaier, A., and Formenti S.C.. 2020. The impact of radiation therapy on innate and adaptive tumor immunity. Semin. Radiat. Oncol. 30:139–144. 10.1016/j.semradonc.2019.12.005 - DOI - PubMed

LinkOut - more resources